Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. Issue 12 (1st December 2020)

• Record Type: Journal Article
• Authors: Ajam, Tarek; Cumpian, Tabitha L; Tilkens, Blair L; Jahangir, Imaan A; Frost, Jared; Ceretto, Cheryl; Jahangir, Arshad
• Is Part Of: Expert review of clinical pharmacology. Volume 13:Issue 12(2020)
• Page Start: 1309
• Page End: 1327
• Publication Date: 2020-12-01
• Subjects: Atrial fibrillation -- elderly -- non-vitamin K antagonist oral anticoagulants -- stroke -- warfarin -- dabigatran -- rivaroxaban -- apixaban -- edoxaban -- drug-drug interaction -- bleeding; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2020.1842191
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in patients with atrial fibrillation (AF). Since NOACs are predominantly used in the elderly with AF at high risk for stroke and bleeding and with comorbidities requiring polypharmacy, it is important to assess their safety and efficacy in this population. Areas covered: We review changes in pharmacokinetics and pharmacodynamics observed with senescence and the effect on NOACs and drug and food interactions. We also provide an update on challenges related to NOAC use in situations that increases the risk for bleeding or require temporary discontinuation and address practical issues in the elderly AF patients managed on NOACs. Clinical studies and trials with cardiovascular outcomes reported from January 1990 to August 2020 were identified through the Medline database using PubMed, Cochrane Library, and EMBASE database. Expert opinion: NOACs are highly effective in preventing stroke in AF patients with non-inferior or superior efficacy to warfarin, with reduced risk of major bleeding. However, in the older-elderly, evidence comes mainly from observational studies or extrapolation from studies in populations with minimal functional limitations or comorbidities. The high upfront cost and out-of-pocket expense for copayment or deductibles also limit the use of this effective therapy in a substantial number of patients. The cost reduction may further improve long-term use for NOACs in stroke prevention in elderly patients with AF.